Targovax ASA ( (GB:0RIS) ) has issued an update.
Circio Holding ASA has announced a strategic partnership with 4basebio PLC to combine their advanced technologies for the development and testing of synthetic DNA vectors. This collaboration aims to leverage Circio’s circVec technology and 4basebio’s DNA vector and delivery platforms to create a robust, non-viral gene therapy platform. The partnership is expected to enhance therapeutic delivery, durability, and cost efficiency, potentially setting new standards in the field of genetic medicine and vaccines.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing cutting-edge circular RNA vector expression technology for next-generation nucleic acid medicine. The company has established a unique platform, circVec, known for its enhanced and durable protein expression, which positions it as a potential future gold-standard in nucleic acid and viral therapeutics. Circio’s research and development activities are conducted by its subsidiary Circio AB at the Karolinska Institute in Stockholm, Sweden, while also advancing a pan-RAS cancer vaccine targeting KRAS driver mutations.
YTD Price Performance: 0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: NOK57.15M
For an in-depth examination of 0RIS stock, go to TipRanks’ Stock Analysis page.